(9ci)-1H-咪唑并[4,5-b]吡啶-7-羧酰胺 | 78316-12-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 中文名称: (9ci)-1H-咪唑并[4,5-b]吡啶-7-羧酰胺
• 中文别名: 3H-咪唑并[4,5-b]吡啶-7-甲酰胺
• 英文名称: 3H-Imidazo[4,5-b]pyridine-7-carboxamide
• 英文别名: 1H-imidazo[4,5-b]pyridine-7-carboxamide
• CAS: 78316-12-8
• 化学式: C₇H₆N₄O
• 分子量: 162.15
• InChiKey: NGNCLFMILGRPPP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  84.7
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• NEW FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AS INHIBITORS OF THE PROTEIN CHAPERONE HSP 90
  申请人：THOMPSON Fabienne

  公开号：US20100130503A1

  公开（公告）日：2010-05-27

  The present invention relates to compounds of formula (I): wherein R1, R 2 , R 2 ′, L, Het, p and p′ are as defined herein, compositions containing them, and their use as medicinal products.

  本发明涉及以下化合物的公式（I）：其中R1、R2、R2′、L、Het、p和p′如本文所定义，以及含有它们的组合物，并将它们用作药品。
• Quinazoline Derivative
  申请人：Mizutani Takashi

  公开号：US20080275069A1

  公开（公告）日：2008-11-06

  This invention provides a compound or its pharmaceutically-acceptable salt of formula (I) wherein R 1 represents a lower alkyl group et al; R 2 and R 3 are same and different and represents hydrogen atm et al; R 4 represents the substituent of the formula (I) et al; X 1 represents NH, O or S; Y represents N or C; Ar is a divalent substituent derived from aryl et al, by removing two hydrogen atoms therefrom; the ring A represents a 5- or 6-membered heteroaryl group; this compounds has a histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect and is useful for preventive or remedy of metabolic system diseases, circulatory system diseases or nervous system diseases.

  本发明提供了式（I）的化合物或其药学上可接受的盐，其中R1代表较低的烷基等；R2和R3相同或不同，分别代表氢原子等；R4代表式（I）的取代基等；X1代表NH、O或S；Y代表N或C；Ar是由芳基衍生的二价取代基等，通过去除其中的两个氢原子而得到；环A表示5-或6-成员杂芳基基团；这些化合物具有组胺H3受体拮抗作用或组胺H3受体反向激动剂作用，并且对于预防或治疗代谢系统疾病、循环系统疾病或神经系统疾病是有用的。
• Imidazo[4,5-B]Pyridine-7-Carboxamides 704
  申请人：Arvidsson Per

  公开号：US20100234593A1

  公开（公告）日：2010-09-16

  The present invention relates to new compounds of formula (I) as a free base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.

  本发明涉及公式（I）的新化合物，其为自由碱或药学上可接受的盐、溶剂或其盐的溶剂，以及制备它们的过程和其中使用的新中间体，含有所述治疗活性化合物的制药配方以及在治疗中使用所述活性化合物的用途。
• QUINAZOLINE DERIVATIVE
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1757594A1

  公开（公告）日：2007-02-28

  This invention provides a compound or its pharmaceutically-acceptable salt of formula (I) wherein R1 represents a lower alkyl group et al; R2 and R3 are same and different and represents hydrogen atm et al; R4 represents the substituent of the formula (II) et al; X1 represents NH, O or S; Y represents N or C; Ar is a divalent substituent derived from aryl et al, by removing two hydrogen atoms therefrom; the ring A represents a 5- or 6-membered heteroaryl group; this compounds has a histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect and is useful for preventive or remedy of metabolic system diseases, circulatory system diseases or nervous system diseases.

  本发明提供了一种式 (I) 的化合物或其药学上可接受的盐 其中 R1 代表低级烷基等；R2 和 R3 相同或不同，代表氢大气等；R4 代表式（II）的取代基等； 该化合物具有组胺-H3 受体拮抗作用或组胺-H3 受体反拮抗作用，可用于预防或治疗代谢系统疾病、循环系统疾病或神经系统疾病。
• BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE
  申请人：Gilead Sciences, Inc.

  公开号：EP3294732A1

  公开（公告）日：2018-03-21